Contraceptive Technology Update – November 1, 2003
November 1, 2003
View Issues
-
Move over, Pill: New contraceptives expand acceptance among women
When discussing contraceptive options with your female patients, what choices are available at your facility? If they include the contraceptive patch (Ortho Evra, Ortho-McNeil Pharmaceutical, Raritan, NJ) and the contraceptive vaginal ring (NuvaRing, Organon, West Orange, NJ), you join the majority of respondents to the 2003 Contraceptive Technology Update Contraception Survey. -
Interest in extended-use contraception to grow
Get ready for a major change to occur in the way birth control pills are prescribed and used with the arrival of Seasonale, the first dedicated extended-regimen oral contraceptive. -
Survey profile
A total of 215 providers participated in the 2003 Contraceptive Technology Update Contraception Survey, which monitors contraceptive trends and family planning issues among readers. -
Readers rank top oral contraceptives
While new birth control methods are attracting attention from new and established contraceptive users, family planning clinicians say many women continue to choose combined oral contraceptives (OCs) for safe, reliable pregnancy prevention. -
Readers share views on common OC challenges
The next patient on your schedule is a 41-year-old woman who smokes 12-15 cigarettes a day. She would like to use combined oral contraceptives (OCs). Will she leave your office with a prescription for the Pill? -
Emergency contraception provision catches on
Just six years ago, a national report asked, Is the secret getting out? when it comes to emergency contraception (EC).1 If results of the 2003 Contraceptive Technology Update Contraception Survey are any indication, ECs message now is being heard loud and clear. -
CTU Updates
ACNM web site offers breast-feeding resources; New condom now available from Trojan; New Arabic web site offers EC information -
Audio conference looks at revolutionary contraceptive
-
A Review of Extended-Cycle Oral Contraception
Seasonale (Barr Laboratories, Pomona, NY), the first extended-cycle oral contraceptive (12 weeks continuous daily active pill followed by a one-week inactive pill) approved by the Food and Drug Administration (FDA) is expected to become clinically available by the end of this month.